Lepromatous leprosy and perianal tuberculosis: a case report and literature review by Maria Parise-Fortes et al.
Parise-Fortes et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2014, 20:38
http://www.jvat.org/content/20/1/38CASE REPORT Open AccessLepromatous leprosy and perianal tuberculosis:
a case report and literature review
Maria Rita Parise-Fortes1,3*, Joel Carlos Lastória1, Silvio Alencar Marques1, Maria Stella Ayres Putinatti1,
Hamilton Ometto Stolf1, Mariângela Ester Alencar Marques2 and Vidal Haddad1Abstract
Leprosy is a chronic infectious disease caused by Mycobacterium leprae, a microorganism that usually affects skin
and nerves. Although it is usually well-controlled by multidrug therapy (MDT), the disease may be aggravated
by acute inflammatory reaction episodes that cause permanent tissue damage particularly to peripheral nerves.
Tuberculosis is predominantly a disease of the lungs; however, it may spread to other organs and cause an
extrapulmonary infection. Both mycobacterial infections are endemic in developing countries including Brazil, and
cases of coinfection have been reported in the last decade. Nevertheless, simultaneous occurrence of perianal
cutaneous tuberculosis and erythema nodosum leprosum is very rare, even in countries where both mycobacterial
infections are endemic.
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Mycobacterium leprae, the causative agent of leprosy
that affects the skin and peripheral nerves, shows trop-
ism for macrophages and Schwann cells. The disease
presents a wide clinical spectrum that is closely related
to the patient specific immune response. The benign
type, referred as tuberculoid or paucibacillary, is charac-
terized by a Th1 immune response and production of
type 1 cytokines including IFN-γ, IL-2, IL-12, IL-15 and
TNF-α, which are typical of strong cell-mediated im-
munity. In lepromatous or multibacillary leprosy, the
main characteristics comprise high levels of Th2-type
cytokines such as IL-4, IL-5 and IL-10, high bacillary
loads in skin lesions and reduced specific cellular im-
munity [1,2].
Tuberculosis is caused by Mycobacterium tuberculosis and
is predominantly a disease of the lungs, with pulmonary tu-
berculosis accounting for 70% of cases [3]. M. tuberculosis
can disseminate to other organs, including lymph nodes,
bones, meninges and other extrapulmonary locations [3].* Correspondence: mfortes@fmb.unesp.br
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article, unless otherwise stated.There are 9 million cases of active tuberculosis being re-
ported annually and one third of the world’s population is
supposed to be infected with Mycobacterium tuberculosis,
although asymptomatically. Of these latent individuals,
only 5-10% will develop active tuberculosis in their life-
time [3-5]. Similarly, in the natural history of leprosy, less
than 5% of the people exposed to M. leprae will develop
clinical disease [6,7].
Infections with intracellular pathogens such as M. leprae
and M. tuberculosis, in most cases, are controlled by the
cell-mediated immune response, based on CD4+ Th1 cells
[8]. Leprosy is a more prevalent cause of cutaneous
infections than tuberculosis and, even in endemic countries,
the coinfection is uncommon in both diseases. We report
in this paper a case of perianal tuberculosis in a patient
whose lepromatous leprosy status was diagnosed as a type
2 leprosy reaction.Case report
A 59-year-old male patient was admitted to our university
hospital (Botucatu, SP, Brazil) complaining of a perianal
suppurative ulcer developed two months before the first
medical consultation. He was under therapy with prednis-
one 40 mg/day for six months due to a presumed diagno-
sis of a drug reaction. On physical examination, a clean
10-cm diameter phagedenic perianal ulcer (Figure 1) andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Cutaneous tuberculosis: fagedenic perianal ulcer.
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region were observed. During investigation, and soon after
reducing the corticosteroid dose, disseminated erythema-
tous papules and nodules were observed in the upper
limbs (Figure 2).
Histopathology of the perianal ulcer revealed a dense his-
tiocytic dermal infiltrate and a granulomatous inflammatoryFigure 2 Lepromatous leprosy: erythematous papules and
nodules on the upper limbs.response with central caseous necrosis (Figure 3). Fite-
Faraco staining showed a few acid-fast bacilli and the
hypothesis of cutaneous tuberculosis was raised. The
histopathology of upper limbs papular and nodular le-
sions showed foamy macrophages with globi of bacilli,
suggesting lepromatous leprosy (Figure 4). The perianal
and inguinal ulcers were considered uncommon mani-
festations of type 2 leprosy developed when corticoster-
oid was gradually diminished. The patient was treated
as for multibacillary leprosy with multidrug therapy and
thalidomide.
Four weeks later, the patient had fever, weight loss, asthe-
nia and worsening of the perianal ulcer (Figure 5), but
without erythema nodosum leprosum. With this clinical
picture, new investigation was developed. The tubercu-
lin skin test was positive (20 × 20 mm) and culture of
M. tuberculosis – using a biopsy sample from the peri-
anal ulcer – on Löwenstein-Jensen medium was positive
(Figure 6). Polymerase chain reaction (PCR) and DNA
analysis from upper limb skin samples were positive for
M. leprae (Figure 7). With the new information the pa-
tient was finally diagnosed as presenting simultaneously
lepromatous leprosy – type 2 reaction – and cutaneous
tuberculosis expressed by the perianal ulcer. Screening for
HIV, HBV or HCV infection as well as lung, renal or
colon compromising were negative. Hence, the patient
was treated with isoniazid, ethambutol and rifampin for
nine months with complete healing of the perianal and in-
guinal lesions after two months (Figure 8). After the tuber-
culosis treatment, the patient was submitted to additional
multidrug therapy for 12 months with dapsone, rifampin
and clofazimine with complete cure of leprosy.
Discussion
Tuberculosis is one of the most important health concerns
in the world, which causes relevant levels of morbidityFigure 3 Histopathological exam of the perianal ulcer showing
a dense histiocytic infiltrate and central caseous necrosis.
Figure 4 Skin nodule consisting of foamy macrophages with
globi of bacilli. Fite-Faraco staining revealed the presence of
lepromatous leprosy acid-fast bacilli.
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tries, in spite of this being the era of human immuno-
deficiency virus infection [9]. The number of tuberculosis
cases in industrialized and developing countries has in-
creased in recent years, followed by increasing multidrug
resistance [10].
Multidrug resistance and HIV infection are predispos-
ing factors for the disease, since the immune response of
the patient plays a significant role on clinical manifest-
ation of tuberculosis [10-12]. Extrapulmonary tubercu-
losis accounts for 13% of all cases [4]. Nevertheless,
cutaneous tuberculosis is uncommon and is reported to
occur in less than 1.5% of the cases of extrapulmonary
tuberculosis [13].
The present study reports a clinical case of perianal
tuberculosis and lepromatous leprosy with type 2 reac-
tion coinfection without any detected active pulmonary
or gastrointestinal infection. The association betweenFigure 5 Cutaneous tuberculosis: phagedenic perianal ulcer
showing worsening of the perianal ulcer after treatment for
leprosy lesion, for two months.
Figure 6 M. tuberculosis, positive culture on Löwenstein-Jensen
medium at 37°C.
Figure 7 M. leprae, positive polymerase chain reaction
DNA analysis.
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thema nodosum leprosum demonstrates an extremely
uncommon occurrence.
Perianal tuberculosis may manifest in the following
forms: ulcer, fistula, abscess, lupoid infiltration or miliary.
The most common type is the ulcerative lesion, which is
likely to have well-defined boundaries and is characterized
by mucopurulent discharge [14]. The lesion observed inFigure 8 Perianal ulcer completely healed with antituberculous
treatment for two months.the present report was ulcerative with many bacilli, signal-
ing an immunosuppressive status probably related to cor-
ticosteroid therapy.
Perianal tuberculosis has rarely been reported, even in
countries where the disease is endemic, and the diagno-
sis is impaired due to the lack of a pulmonary focus. The
possibility of an association with intestinal tuberculosis
should be further investigated [15,16].
Coinfection with pulmonary tuberculosis and leprosy
type 1 reaction has been reported and the leprosy type 1
reaction was observed during the treatment of pulmon-
ary tuberculosis [17]. According to Trindade et al. [17],
a review of patients between 2004 and 2011 showed that
only two patients with leprosy were diagnosed as coin-
fected with pulmonary tuberculosis. The occurrence of
both tuberculosis and leprosy in the same individual is
not an unusual clinical condition, but it is scarcely re-
ported in the literature, even in countries where both
diseases are endemic [18].
Delobel et al. [19] reported a triple association of American
cutaneous leishmaniasis, lepromatous leprosy and pul-
monary tuberculosis. The authors suggested that the unre-
sponsiveness of patient’s T cells to IL-12 in vitro, stimulated
by either L. guyanensis, M. bovis BCG or M. leprae anti-
gens, could be the evidence of patient’s T cells failure to
produce an appropriate Th cell response. This was respon-
sible for the triple reported coinfection. There are other
reports in the literature of coinfection of leprosy and pul-
monary tuberculosis as well as leprosy and disseminated tu-
berculosis in HIV-infected patients [20-24].
Leprosy is a disease of poverty. Its diagnosis remains
based on clinical signs and symptoms. Delayed diagnosis
associated with nerve impairment and physical deform-
ities is still common in several endemic areas throughout
the globe. Improving the medical attention and infrastruc-
ture and promoting sanitary education will provide earlier
diagnosis and specific treatment, which are crucial to help
interrupt the M. leprae transmission chain [25,26]. Both
leprosy and tuberculosis pose significant health risks,
making it important for physicians to diagnose accurately
and provide appropriate treatment for patients [27].
CD4+ T cells, as well as the cytokines IL-12, IFN-γ
and TNF-α, are critical in the control of M. tuberculosis
and M. leprae infections, but the host factors that deter-
mine why some individuals are protected from infection
while others develop the disease are still unclear [28].
Hence, the reason why M. tuberculosis and M. leprae are
able to evade host immune surveillance and persist in-
side the macrophages remains to be understood. These
pathogens inhibit phagosome-lysosome fusion and stop
phagosome maturation at an early stage, thus allowing
escape from microbicidal peptides [29].
Genetic factors of the host and of the pathogen itself
may be associated with an increased risk for patients to
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munologic deficits observed in leprosy are specific for
M. leprae. Immunosupression has been observed to ren-
der individuals susceptible to M. leprae and M. tubercu-
losis in cases of transplantation, cancer chemotherapy
and in treatment with antitumor necrosis factor agents
[30-32]. However, the coinfection with lepromatous lep-
rosy and tuberculosis probably depends on multiple fac-
tors including low socioeconomic status, poor nutrition,
chemotherapy-induced immunosuppression and defi-
cient host immune response [27].
The present report shows a rare case which was prob-
ably eased by the immunosuppressive effect of cortico-
steroid therapy for six months. Cutaneous tuberculosis
remains to be one of the most difficult conditions to
diagnose in developing countries due to the lack of re-
sources and the necessary observation of clinical and
histopathologic findings [11,33,34]. To the best of our
knowledge, this is the first case of lepromatous leprosy
associated with erythema nodosum leprosum and peri-
anal tuberculosis fully documented.
Conclusion
In the present study, we report an association of leproma-
tous leprosy with type 2 reaction and perianal ulcerative tu-
berculosis without previous or active pulmonary infection.
Simultaneous occurrence of cutaneous tuberculosis and
lepromatous leprosy is extremely infrequent, even in coun-
tries where both mycobacterial infections are endemic.
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